We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Angle Plc | AGL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.375 | 2.63% | 14.625 | 10:18:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 14.25 | 14.25 | 14.625 | 14.625 | 14.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 25/7/2024 17:08 by bones698 Snake wow I can see your delusional the house broker gets the figure from. Guidance from the company. Plus agl themselves said they expected revenues to triple from 2.2mYour showing your new here tbh I've heard it all before from. Far more informed people than yourself but look where it ended up. You mean the same Gdr that I tripled my money on wow that's a shocker of an investment while agl looks so good you buffoon. Time to add you to filter before things get worse for you |
Posted at 23/7/2024 08:33 by ohwhatfun Just read the AGM notes Timbo thanks, and replies.Fund raise. No some were not saying trouble fund raising, they said trouble raising the typical required amount £20m. Previous raises have been £20m with more cash in the bank at the time of the raise. Had they raised £20m, as per posts, various new private investors would have bought, others would add. Instead you have a number of investors doubtful of revenue claims, knowing that event triggers negative news, and the miss shortens the time to the next raise. Why it’s difficult to raise currently at prices and amounts is in the notes. Some mention Avacta 50p raise 75p now, it was over £1 shortly before the raise, with posters trashing others who suggested a big discounted raise was coming. Revenue this year HOPE to get 2 more customers this year, what over £2m each against examples of £150k. Not confident or very confident, HOPE. Oversubscribed raise, show me news of raises where they are not oversubscribed over the years. It’s been explained a number of times, fund raises are supposed to be closed circles but are far from it. In the subscribed list for AGL would have been demand to close short positions opened in knowledge of the raise. Just about every raise sees the share price fall below the raise price, yet AGL seem oblivious to this, suggesting incompetence. The loss of bread and butter small company revenue in this sector is evident in other companies, 75%+ revenue drops in some cases, explained as funding drying up. That’s not AGL that’s the sector. AGLs fix was to proactively start chasing big Pharma. All the confidence and loud claims now seems to be based on 2 with HOPE. Hope based on hard-nosed sale tactics. Yeah the deal is you pay for everything, we keep the IP you create and paid for. I fail to see the buyer carrot on a stick there, minnows trying to bully majors. The hope of 2 more customers, needs to be done swiftly to count for revenue this year. It sounds like revenue is going to be missed by some way. That’s not a good advert for new investors to buy now. Some don’t like coin flip investment timing |
Posted at 18/7/2024 20:20 by bones698 Atm it's hard to see where the required revenues will come from. We all know even adw, that there is the potential for some large deal with AGL nobody denies that but the relaity thius far hasn't shown the big numbers are coming. Even stage 2 with the likes of AZ and eisai are for 1-3 m and they aren't at that stage with them yet. Illumia could be but seems more like a gradual increasing deal selling to their clients so not a fixed deal.Then you have to consider that we are welll past half way in 2024 and the revenues won't them all be added into this year's numbers but mostly rolll over to next year. The value of the contracts spread out over the length of the deal announced. With that said finding over 5m in revenues looks a long shot. I suspect a revenue miss is coming and we all know the impact that could have on the share price here. There's some conflicting signals with dermot increasing his holding and illumia panels being worked on with news on them soon according to AN. There has been a lot of progress made, the deals with AZ are not to be sniffed at and the first one is due end of October so we will see if that translates into a bigger deal as intimated by AN in the presentations. For me the odds are on a revenue miss but there is always the chance of the rabbit out of the hat with AGL. The last revenue miss was by a mere 200k which resulted in a drop from around 40p down to around 15p. For me this might explain why they raised money recently too but also they raised money to avoid a going concern on the accounts. Its all part of the game aim is a big gambling wheel, getting the timing right is always a big part of how well your investments do. For now I'm out and looking for a point to re-enter. The interims aren't too far away in september so I might wait to see what they say in them. |
Posted at 12/7/2024 22:20 by bones698 Unfortunately my random guesses have proved pretty good with AGL over the years. I've done OK put of agl which not many can say so far tbh.i do want to buy back in at some point but it seems there is no rush after some of the feedback from the agm. I'll wait to see the TU next month first |
Posted at 30/6/2024 09:06 by miavoce For contrast, the view of BigBiteNow on the other site.I really don't understand what this £2m cash burn per month is being built from other than a desire to paint a bad picture. In 2023 AGL actual FY cash burn was c. £16m. That's equal to £1.33m cash burn per month. But the YE end cash position was £16.2m vs. £22.2m on 30th June indicating a cash burn in H2 2023 of c. £6m which is £1,000,000 per month. In addition further cost savings are expected in 2024. "The streamlining is expected to deliver cost savings of c. £3 million per annum in 2024 resulting in the extension of the cash runway into Q2 2025." They are worth up to £250k per month. They may not achieve all of them, but any further improvement is a positive for that cash burn. Then we have increasing revenues. H2 cash burn was achieved against just £1m in revenues. So far this year revenues are reportedly running at c. £2.6m with more to come. Again they may not reach their £6.45m goal but they are already ahead of last year with c. 6 months more still to go. This will also help lower monthly cash burn. Nowhere is any of the available information is there evidence that AGL is burning anywhere near £2m a month. YE cash was £16.2m + £8.77m raised = c. £25m minus placing costs. On the above evidence, AGL has at least 12 months before any questions need to be raised over further funding and it is fair to expect that multiple deals will be landing in that timescale. |
Posted at 07/6/2024 19:09 by ohwhatfun This is a repeat of Avacta, pumpers and the naive not paying attention to detail and warnings from posters that a raise is coming.Posts of no need, not until next year, CEO says no, up front payment deal, other ways. 50p raise came, then more warnings by the savvy that it will drop more. 20% down on the raise so far. It’s not an advantage of being blessed with clairvoyance. It’s simply experience of watching it happen over and over again on share after share. Typical signs, repeat news pre raise, buoyant CEO, rejecting of negative views about placings. Yes the CEO could say and believe that, but get outvoted at a board meeting about funding. Then comes the silence when a host of posters warn about it. Fund raises run for a typical minimum of 2 weeks, with obvious prior knowledge at least a few days before (company decision). Brokers then hunt for backers, so the word spreads, some show interest, some don’t, but the web of who knows expands quickly. AGL didn’t play ball to the vultures, on the discount wanted. They will now be circling, wagering that AGL will miss revenue and be back with the begging bowl later this year. It could be brutal. I hope for investors and cancer sufferers that AGL see some major traction in the coming months. It’s highly frustrating to see such life changing tests being over-looked. |
Posted at 05/6/2024 12:22 by boris cobaka I'd forgotten about the Crescendo clinical services contract.The more success these partners have in their trials the greater the need for AGL services. The repeat business is crucial and helps to drive further expansion as the services become more established. The ongoing success of the candidates in trial will necessitate continued support from AGL. In the case of Crescendo the trial is in conjunction with Keytruda which is I believe a Merck drug. More exposure to large Pharma in such instances will help their cause. So important to monitor the partnership development stories which won't require AGL to issue an rns each time the partner releases an update. Interesting times for AGL. But in the words of ginger midget... "Money's too tight to mention.....' |
Posted at 04/6/2024 09:19 by 5oletrader We know AGL are attending EACR 2024. I note that on:Monday 10th June 202412:15-13:00'More to see with liquid biopsy' is a 2 part presentation.- Part 1: 'Liquid biopsy as a research tool'Anna Babayan - Illumina, Germany Part 2: 'Liquid biopsy multi-analyte approach to decipher treatment resistance in prostate cancer'Amin El-Heliebi - Medical University of Graz, Austria-Does this TERMINOLOGY sound familiar? ILLUMINA - Liquid biopsy analyses opened up new avenues to better understand development and progression of cancer and apply so called precision medicine. Whereas clinical applications are mostly limited to single omic data, in research setting multiomics data provide rich insights and enable new discoveries. In particular CIRCULATING TUMOR CELLS represent a rich source of tumor-related information and can be analysed on genomic, transcriptomic, epigenomic and proteomic levels. In addition, viable cells can be utilized for drug screening assays. In ADDITION, CIRCULATING TUMOR DNA and RNA provide COMPLEMENTARY insights multiplying discovery pover of liquid biopsy analysis. Join our symposium "More to see with liquid biopsy" to learn how multi-analyte multiomic liquid biopsy analyses can enable discoveries of new prognostic and predictive biomarkers and potential drug targets. Dr. Anna Babayan (Illumina) will give a short introduction into the current state of liquid biopsy as a research tool and Ass. Prof. Amin El-Heliebi (Austria) will discuss how multi-analyte liquid biopsy analysis enables translational applications such as analysis of treatment resistance in prostate cancer.Https://nwm.c |
Posted at 29/4/2024 07:39 by ohwhatfun GspannerThe news caught attention, some will have had AGL sat in the background waiting for interest/traction, lurking rather than avid followers. Check out the share price performance and confusing lack of interest in recent years in their tech. AZ prompt a look, time to buy? The deeper look shows last raise £20m in 2022 at 80p. Various forecasts of a cash runway, H2 2024 to Q1 25 to into Q2 25. The last business update included, slower than expected. The small cap market has been decimated, share prices obliterated, a mass of examples of angry investors where large discounts have been in play and share price collapses immediately before fund raises. Posts of yeah buy now big deal, but sensible, risk averse investors look at the full picture. AGL appear to have left it later in the day to raise funds than usual, perhaps hoping for a higher share price on the back of news. The market knows they need money, the market is highly risk averse, so if AGL go to market for funding, the market will drop the share price and discount from there. If 15p is to be the share price pre fund raise game, then a 10p raise would be generous. It’s just sober market opinions, unaffected by holding (loss or profits). Typically those shouting the loudest pumping, are looking for a quick exit, knowing the loitering cash issue will impact the share price. Chances of avoiding dilution are unknown, it’s a coin flip. How many avoid it is the best guide pretty much all have had major dilution with some failing to attract funding at all. That’s how some see it, it’s opinions based on the reality of the market. The chance of normal market behaviour on a fund raise for AGL, is high. |
Posted at 21/4/2024 16:24 by 5oletrader Something to keep an eye on?- ROCHE snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use ROCHE isn't content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations. With 1.5 BILLION Swiss francs ($1.65 BILLION) in 2023 sales, Alecensa is the top-selling med in the ALK inhibitor class, which also includes Takeda's Alunbrig and Pfizer's next-generation ALK/ROS1 inhibitor Lorbrena. ?Besides the adjuvant setting for resected tumors, ROCHE is also testing Alecensa in patients with locally advanced, unresectable, stage 3 NSCLC in the phase 3 HORIZON-01 trial.Https://www.fi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
